Yasuto Takeuchi

8PUBLICATIONS
54CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 12, 2026
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

|Nov 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Aug 28, 2025
Prognostic Impact of Gastrointestinal Immune-Related Adverse Events Depends on Nutritional Status in Cancer Patients Treated with Immune Checkpoint Inhibitors.

Shoichiro Hirata, Yoshiyasu Kono, Emi Tanaka

|Aug 21, 2025
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Takeshi Hatanaka, Shigeo Shimose, Takanori Ito

|Mar 15, 2024
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.

Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso

|Aug 04, 2023
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.

Yasuto Takeuchi, Kazuhiro Nouso, Shin-Ichi Fujioka

Pageof 2

Frequent Collaborators

3 joint publications

Kazuhiro Nouso

3 joint publications

Kazuya Kariyama

3 joint publications

Motoyuki Otsuka

3 joint publications

Takumi Kawaguchi